Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

This was the stock's second consecutive day of gains.

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

which could take on rival Merck & Co's best-selling drug Keytruda. The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert said.

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

Merck (MRK) has reportedly been in talks to acquire Swiss biotech company MoonLake Immunotherapeutics (MLTX) for over $3 billion, according to the Financial Times. Snowflake (SNOW) will buy ...